重组人血管内皮抑素联合化疗方案治疗晚期非小细胞肺癌66例临床观察

目的:探讨重组人血管内皮抑素联合化疗方案治疗晚期非小细胞肺癌的临床效果。方法:选取2006年7月-2010年3月就诊于我院的非小细胞肺癌患者66例,将患者平均随机分为两组,各33例,综合治疗组采用重组人血管内皮抑素和化疗药联合治疗;单纯化疗组使用化疗药物治疗。结果:综合治疗组治疗有效率为48.5%,疾病控制率为84.8%。单纯化疗组有效率为24.2%,疾病控制率63.6%。两组比较差异有统计学意义,P<0.05。毒副反应、KPS评分改善无显著差异,P>0.05。结论:应用重组人血管内皮抑素可以有效辅助化疗药作用于肿瘤,无明显加重化疗毒副作用,值得临床推广。

66 Cases of Clinical Research on SCLC

Objective：Discussing clinical effects of non-small-cell carcinoma in later period with united chemotherapy by recombining human vessel endothelium chalones.Methods：By selecting 66 cases of non-small-cell carcinoma patients who have been treated in our hospital from July,2006-Mar.2010,the patients are divided into two groups randomly on average with 33 cases in each group.The comprehensive therapy group adopts recombined human vessel endothelium chalones and chemotherapy medicines for combined treatment while pure chemotherapy group employs chemotherapy medicines for treatment.Results：The effective rate of treatment for the former group is 48.5% with disease control rate 84.8% while those of the latter are 24.2% and 63.6% respectively.Remarkable differences occur to both groups in that P0.05 with no big differences in toxic side effect and KPS grading improvement,P0.05.Conclusion：The application of recombining human vessel endothelium chalones can effectively assist chemotherapy medicine to cure tumours without aggravating toxic side effects of chemotherapy,so it is worth being applied to clinical therapy.